Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the CDK4/6 inhibitor palbociclib may protect human hair follicles from the damaging effects of taxane chemotherapy by inducing G1 arrest in stem/progenitor cells.

This study identified a nonfunctional Itpr3 gene in BTBR mice, attributed to a 12-bp deletion, which likely causes their simultaneous hair loss and taste perception deficits.

This study concluded that KLF4 is a crucial regulator of hair follicle stem cell quiescence and may work by interacting with multiple transcription factors to control related genes.

This study developed the mTurquoise2-Col4a1 mouse model and used fluorescent tagging of collagen IV to offer new insights into basement membrane dynamics during hair follicle budding, revealing that basement membranes are flexible and stable structures in developing skin tissue.

This study found that Baricitinib significantly reduced hair loss and immune response in a mouse model of alopecia areata.

This article from the 4th Intercontinental Meeting of Hair Research Societies provides no abstract or new findings.

This study identifies the PI4P-RHD4 module as a key regulator of GET pathway receptor dynamics in Arabidopsis, affecting TA protein insertion and root hair growth.

This study observed that, among alopecia areata patients in Fujian, China, lower IgG4 levels and higher IFN-γ levels were statistically significant, suggesting their potential role as biomarkers for the condition and highlighting avenues for future therapeutic developments.

Eyebrow and eyelash regrowth usually matches scalp hair response in alopecia areata patients treated with baricitinib.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

This study found that baricitinib, when administered consistently over three years, maintained its efficacy in patients with severe alopecia areata who responded by Week 52 with notable hair regrowth, indicated by a SALT score of ≤20.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

In this study, baricitinib, a JAK inhibitor, was found to significantly improve scalp hair regrowth in both adults and adolescents with severe alopecia areata, with many achieving nearly full regrowth by weeks 36 or 52.

This abstract contains only a photo caption and does not provide research findings.

This study found that BMP receptor IA is crucial for hair progenitor cell differentiation in mice, and its sequential inhibition and activation are necessary to generate a functioning hair shaft.

This study reported that ritlecitinib 50 mg and baricitinib 4 mg showed similar efficacy in treating severe alopecia areata, with no significant difference in hair regrowth outcomes at Week 24, but there remains considerable uncertainty and a need for further research.

This review discusses the molecular mechanisms and clinical applications of thymosin β4, highlighting its potential benefits for inflammation, wound healing, tumor metastasis, and other medical conditions but reports no new experimental results.

This study focused on baricitinib's effect on patients with severe alopecia areata, highlighting its efficacy for hair regrowth and its potential to improve health-related quality of life and psychological symptoms, as seen in two phase 3 trials.

This study found that hypaphorine alters cytoskeletal organization in Eucalyptus globulus root hairs, contributing to reduced root hair elongation by possibly disrupting vesicle delivery needed for growth.

This invitation letter for the 2004 Annual Scientific Meeting of the International Society of Hair Restoration Surgery provides no new research findings, focusing instead on welcoming attendees to the event.

This study found that Ber-EP4 immunoreactivity is present in specific areas of hair follicles across different stages of the hair cycle, particularly in the secondary hair germ, but not in mature anagen follicles.

This study found that immunohistochemistry can effectively distinguish between tricholemmoma and basal cell carcinoma, with BerEP4 and CD34 serving as key differentiators.

This study found extensive real-world and clinical trial exposure to baricitinib across various disease states, ages, and racial populations, contributing data to its overall profile.

This study found that specific genetic variations in the IRF2BP2 gene influence fleece structure in sheep, with one variant completely determining coat type and another significantly modifying fiber characteristics, providing valuable insights for improving fleece quality through selective breeding.

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

This study provides evidence that ILC1-like cells can induce alopecia areata in previously healthy human hair follicles, challenging the view that it is solely an autoantigen-dependent autoimmune disease.

This study describes the use of a genetically engineered mouse model, mTurquoise2-Col4a1, to fluorescently label collagen IV and observe basement membrane dynamics during skin development, revealing its stability and pliability during rapid growth phases.